CLAIMS

1. A compound of formula (3Z,5S)-5-(hydroxymethyl)-1-[(2′-methyl-1,1′-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime.

2. The compound according to claim 1, wherein said compound is provided in substantially pure form.

3. The compound according to claim 2, wherein the purity of the substantially pure form is at least in the range of 85% to 99.9%.

4. The compound according to any one of the preceding claims, wherein said compound is an oxytocin receptor antagonist.

5. The compound according to any one of the preceding claims, wherein said compound is a vasopressin V1a receptor antagonist.

6. The compound according to any one of the preceding claims, wherein said compound inhibits the uterine contractions.

7. The compound according to any one of the preceding claims, wherein said compound is administered to a subject in need thereof in a single dose of 50 mg to 900 mg.

8. The compound according to claim 7, wherein said single dose is preferably of 100 mg to 600 mg.

9. The compound according to any one of the preceding claims, wherein said compound is administered concomitantly or separately with at least one compound selected from the group comprising calcium channel blockers, magnesium sulfate, selective prostaglandin modulators, beta-2-adrenergic agonists, beta-3-adrenergic receptor agonists, and/or corticosteroids.

10. The compound according to any one of the preceding claims, wherein said compound is stable in the plasma.

11. The compound according to any one of the preceding claims, wherein the subject in need thereof is a mammal, preferably a human.

12. A compound according to any one of claims 1-11, for use as a medicament.

13. ~~A~~ Use of ~~a~~ a compound according to any one of claims 1-11, in the manufacture of a medicament for ~~use in~~ the treatment and/or prevention, in a subject in need thereof, of disorders associated with the oxytocin receptor activity and/or vasopressin V1a receptor activity;~~.~~ wherein the disorders are selected from the group comprising preterm labor, premature birth, dysmenorrhea, premature ejaculation, sexual dysfunction, endometriosis, embryo implantation failure due to uterine contractions, infertility, benign prostatic hyperplasia, neuro-psychiatric disorders, autism, social behavior disorders, psycho-social stress, and/or cardiovascular disorders.

~~14. The compound according to claim 13, wherein disorders associated with the oxytocin receptor activity are selected from the group comprising preterm labor, premature birth, dysmenorrhea, premature ejaculation, sexual dysfunction, endometriosis, embryo implantation failure due to uterine contractions, infertility, benign prostatic hyperplasia, neuro-psychiatric disorders, autism, social behavior disorders, psycho-social stress, and/or cardiovascular disorders.~~

1~~4~~5. A pharmaceutical composition comprising a compound according to any one of claims 1-11 and a pharmaceutically acceptable carrier, diluent or excipient.

156. The pharmaceutical composition according to claim 145, wherein the administration is made by oral, vaginal or intravenous route.

167. A process for preparing and isolating the compound according to any one of claims 1-11 in substantially pure form comprising the steps of:

a) Loading a crude isomeric mixture comprising a compound of formula (3Z,5S)-5-(hydroxymethyl)-1-[(2′-methyl-1,1′-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime, and/or an active metabolite thereof, on a Silica gel chromatography column;

b) Purifying with 1% alcohol in organic solvent; and

c) Purifying with 2% alcohol in organic solvent.

178. UseA of a a compound according to any one of claims 1-11, in the manufacture of a medicament for the treatment of infertility, the medicament for use in assisted reproduction technology.

189. UseA of a a compound according to any one of claims 1-11, in the manufacture of a medicament for use in the treatment of infertility by *in vitro* fertilization-embryo transfer (IVF-ET) method.

1920. UseA of a compound according to any one of claims 1-11, in the manufacture of a medicament for the treatment of infertility, the medicament for use in reducing embryo implantation failure due to uterine contractions.

201. UseA of a compound according to any one of claims 1-11, in the manufacture of a medicament for reducing the risk of having extrauterine pregnancy, the medicament for use in reducing contractions occurring during the embryo transfer.

212. Use ofA a compound according to any one of claims 1-11,in the manufacture of a medicament for for use in the treatment and/or prevention of a disease relating to oxytocin-induced vascular contractility, vasopressin-induced vascular contractility, oxytocin-induced muscular contractility, vasopressin-induced muscular

contractility.

CLAIMS

1. A compound of formula (3Z,5S)-5-(hydroxymethyl)-1-[(2′-methyl-1,1′-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime.

2. The compound according to claim 1, wherein said compound is provided in substantially pure form.

3. The compound according to claim 2, wherein the purity of the substantially pure form is at least in the range of 85% to 99.9%.

4. The compound according to any one of the preceding claims, wherein said compound is an oxytocin receptor antagonist.

5. The compound according to any one of the preceding claims, wherein said compound is a vasopressin V1a receptor antagonist.

6. The compound according to any one of the preceding claims, wherein said compound inhibits the uterine contractions.

7. The compound according to any one of the preceding claims, wherein said compound is administered to a subject in need thereof in a single dose of 50 mg to 900 mg.

8. The compound according to claim 7, wherein said single dose is preferably of 100 mg to 600 mg.

9. The compound according to any one of the preceding claims, wherein said compound is administered concomitantly or separately with at least one compound selected from the group comprising calcium channel blockers, magnesium sulfate, selective prostaglandin modulators, beta-2-adrenergic agonists, beta-3-adrenergic receptor agonists, and/or corticosteroids.

10. The compound according to any one of the preceding claims, wherein said compound is stable in the plasma.

11. The compound according to any one of the preceding claims, wherein the subject in need thereof is a mammal, preferably a human.

12. A compound according to any one of claims 1-11, for use as a medicament.

13. Use of a compound according to any one of claims 1-11, in the manufacture of a medicament for the treatment and/or prevention, in a subject in need thereof, of disorders associated with the oxytocin receptor activity and/or vasopressin V1a receptor activity; wherein the disorders are selected from the group comprising preterm labor, premature birth, dysmenorrhea, premature ejaculation, sexual dysfunction, endometriosis, embryo implantation failure due to uterine contractions, infertility, benign prostatic hyperplasia, neuro-psychiatric disorders, autism, social behavior disorders, psycho-social stress, and/or cardiovascular disorders.

14. A pharmaceutical composition comprising a compound according to any one of claims 1-11 and a pharmaceutically acceptable carrier, diluent or excipient.

15. The pharmaceutical composition according to claim 14, wherein the administration is made by oral, vaginal or intravenous route.

16. A process for preparing and isolating the compound according to any one of claims 1-11 in substantially pure form comprising the steps of:

a) Loading a crude isomeric mixture comprising a compound of formula (3Z,5S)-5-(hydroxymethyl)-1-[(2′-methyl-1,1′-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime, and/or an active metabolite thereof, on a Silica gel chromatography column;

b) Purifying with 1% alcohol in organic solvent; and

c) Purifying with 2% alcohol in organic solvent.

17. Use of a compound according to any one of claims 1-11, in the manufacture of a medicament for the treatment of infertility, the medicament for use in assisted reproduction technology.

18. Use of a compound according to any one of claims 1-11, in the manufacture of a medicament for the treatment of infertility by *in vitro* fertilization-embryo transfer (IVF-ET) method.

19. Use of a compound according to any one of claims 1-11, in the manufacture of a medicament for the treatment of infertility, the medicament for use in reducing embryo implantation failure due to uterine contractions.

20. Use of a compound according to any one of claims 1-11, in the manufacture of a medicament for reducing the risk of having extrauterine pregnancy, the medicament for use in reducing contractions occurring during the embryo transfer.

21. Use of a compound according to any one of claims 1-11,in the manufacture of a medicament for the treatment and/or prevention of a disease relating to oxytocin-induced vascular contractility, vasopressin-induced vascular contractility, oxytocin-induced muscular contractility, vasopressin-induced muscular contractility.